Trial Outcomes & Findings for The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D) (NCT NCT02867436)

NCT ID: NCT02867436

Last Updated: 2024-09-19

Results Overview

Area under the curve of C-peptide in MMT test at 0, 30, 60, 90 and 120 minutes.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

45 participants

Primary outcome timeframe

Month 1 (baseline) - Month 12 (end of intervention)

Results posted on

2024-09-19

Participant Flow

Participant milestones

Participant milestones
Measure
Gluten-free Diet
Gluten-free diet for pediatric patients with type 1 diabetes
Conventional Diet
Conventional gluten-containing diet for pediatric patients with type 1 diabetes
Overall Study
STARTED
26
19
Overall Study
COMPLETED
20
19
Overall Study
NOT COMPLETED
6
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Gluten-free Diet
n=26 Participants
Gluten-free diet for pediatric patients with type 1 diabetes
Conventional Diet
n=19 Participants
Conventional gluten-containing diet for pediatric patients with type 1 diabetes
Total
n=45 Participants
Total of all reporting groups
Age, Categorical
<=18 years
26 Participants
n=26 Participants
19 Participants
n=19 Participants
45 Participants
n=45 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=26 Participants
0 Participants
n=19 Participants
0 Participants
n=45 Participants
Age, Categorical
>=65 years
0 Participants
n=26 Participants
0 Participants
n=19 Participants
0 Participants
n=45 Participants
Age, Continuous
10.7 years
STANDARD_DEVIATION 3.2 • n=26 Participants
10.1 years
STANDARD_DEVIATION 3.5 • n=19 Participants
10.2 years
STANDARD_DEVIATION 3.3 • n=45 Participants
Sex: Female, Male
Female
13 Participants
n=26 Participants
3 Participants
n=19 Participants
16 Participants
n=45 Participants
Sex: Female, Male
Male
13 Participants
n=26 Participants
16 Participants
n=19 Participants
29 Participants
n=45 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Czechia
26 participants
n=26 Participants
19 participants
n=19 Participants
45 participants
n=45 Participants

PRIMARY outcome

Timeframe: Month 1 (baseline) - Month 12 (end of intervention)

Area under the curve of C-peptide in MMT test at 0, 30, 60, 90 and 120 minutes.

Outcome measures

Outcome measures
Measure
Gluten-free Diet
n=20 Participants
Gluten-free diet Gluten-free diet
Conventional Diet
n=19 Participants
Conventional diet
Change in C-peptide Area Under the Curve Measured by Mixed-meal Tolerance Test (MMTT) Between Group on GFD and Standard Gluten-containing Diet.
1539 pmol*min/l
Standard Deviation 1255
1173 pmol*min/l
Standard Deviation 1006

SECONDARY outcome

Timeframe: Month 1 (baseline) - Month 6 - Month 12 (end of intervention)

Outcome measures

Outcome measures
Measure
Gluten-free Diet
n=20 Participants
Gluten-free diet Gluten-free diet
Conventional Diet
n=19 Participants
Conventional diet
Changes in Mean HbA1c at 6 and 12 Months Relative to Baseline at Month 1.
HbA1c at 6 months
44.8 mmol/mol
Standard Deviation 6.3
47.2 mmol/mol
Standard Deviation 8.3
Changes in Mean HbA1c at 6 and 12 Months Relative to Baseline at Month 1.
HbA1c at 12 months
44 mmol/mol
Standard Deviation 9.5
52.2 mmol/mol
Standard Deviation 10.6

SECONDARY outcome

Timeframe: Month 1 (baseline) - Month 6 - Month 12 (end of intervention)

Outcome measures

Outcome measures
Measure
Gluten-free Diet
n=20 Participants
Gluten-free diet Gluten-free diet
Conventional Diet
n=19 Participants
Conventional diet
Changes in Mean Insulin Dose at 6 and 12 Months Relative to Baseline at Month 1.
Insulin dose at 6 months
0.41 U/kg/day
Standard Deviation 0.17
0.62 U/kg/day
Standard Deviation 0.23
Changes in Mean Insulin Dose at 6 and 12 Months Relative to Baseline at Month 1.
Insulin dose at 12 months
0.50 U/kg/day
Standard Deviation 0.22
0.75 U/kg/day
Standard Deviation 0.34

SECONDARY outcome

Timeframe: Month 1 (baseline) - Month 12 (end of intervention)

Outcome measures

Outcome measures
Measure
Gluten-free Diet
n=20 Participants
Gluten-free diet Gluten-free diet
Conventional Diet
n=19 Participants
Conventional diet
Changes in Immunological Parameters (FoxP3 Tregs, Th1 and Th17 Counts) at 12 Months Relative to Baseline at Month 1.
TEMRA cells at 12 months
8 % of cells
Standard Deviation 2.2
12.5 % of cells
Standard Deviation 3.5
Changes in Immunological Parameters (FoxP3 Tregs, Th1 and Th17 Counts) at 12 Months Relative to Baseline at Month 1.
T-regulatory cells type 1 at 12 months
1.02 % of cells
Standard Deviation 0.63
0.46 % of cells
Standard Deviation 0.16

SECONDARY outcome

Timeframe: Month 1 (before intervention) - Pooled values throughout the intervention (months 3-12) - Month 15 (after intervention)

Measures are shown as pooled values at all timepoints during the intervention period compared to control group throughout the same time-period.

Outcome measures

Outcome measures
Measure
Gluten-free Diet
n=22 Participants
Gluten-free diet Gluten-free diet
Conventional Diet
n=19 Participants
Conventional diet
Differences in Fecal Microbiome Between Children on Normal Diet and Children on Gluten-free Diet Over the First Year of Diabetes Duration
Bifidobacterium
3.3 Percentage of microbes
8 Percentage of microbes
Differences in Fecal Microbiome Between Children on Normal Diet and Children on Gluten-free Diet Over the First Year of Diabetes Duration
Roseburia
3.2 Percentage of microbes
1.2 Percentage of microbes
Differences in Fecal Microbiome Between Children on Normal Diet and Children on Gluten-free Diet Over the First Year of Diabetes Duration
Lachnospira
1.01 Percentage of microbes
0.21 Percentage of microbes

Adverse Events

Gluten-free Diet

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Conventional Diet

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Zdeněk Šumník, PI

Motol University Hospital

Phone: +420702000087

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place